Detailed Office Action
Notice of Pre-AIA or AIA Status
The present application is being examined under the pre-AIA first to invent provisions.
Status of the Claims
Acknowledgement is hereby made of receipt and entry of the communication filed 12 August, 2026. Claims 1-19 are pending in the instant application. Applicant’s election of Group III (claims 11-14) without traverse is noted. Claims 1-12 and 15-19 have been withdrawn from further consideration by the Examiner, pursuant to 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention.
37 C.F.R. § 1.98
The information disclosure statements filed 24 April, 2024, 16 August, 2024, 14 October, 2024, and 11 September, 2026 (5), have been placed in the application file and the information referred to therein has been considered.
37 C.F.R. § 1.84
Acknowledgement is hereby made of receipt and entry of the drawings filed on 24 April, 2024, which are deemed to be acceptable.
Joint Inventors, Common Ownership Presumed
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were effectively filed absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned at the time a later invention was effectively filed in order for the examiner to consider the applicability of 35 U.S.C. § 102(b)(2)(C) for any potential 35 U.S.C. § 102(a)(2) prior art against the later invention.
Graham v. Deere
The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 U.S.P.Q. 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
35 U.S.C. § 103
The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 11-14 are rejected under 35 U.S.C. § 103 as being unpatentable over the combined teachings of Smith et al. (U.S. Pat. No. 10,953,089 B1, issued 23 March, 2021, and claiming priority to Prov. Appl. No. 62/966,271, filed 27 January, 2020; hereinafter referred to as “Smith et al. (‘089)”), Muik et al. (U.S. Pat. No. 12,186,387 B2, issued 07 January, 2025, and claiming priority to Prov. Appl. No. 63/283,976, filed 29 November, 2021; hereinafter referred to as Muik et al. (‘387)”), and Gorman et al. (2021). The claims are directed toward a method of boosting an immune response against SARS-CoV-2 or a heterogeneous SARS-CoV-2 strain thereof in a human comprising administering:a first immunogenic composition comprising (a) one or more first SARS-CoV-2 S glycoproteins having at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to SEQ ID NO: 329, and (b) a pharmaceutically acceptable buffer;wherein the immunogenic composition is administered after administration of another immunogenic composition intended to produce an immunogenic response against SARS- CoV-2 or a heterogeneous SARS-CoV-2 strain thereof in the human (claim 11). Claims 12 and 13 are directed toward the timing of administration. Claim 14 references a priming immunogenic composition comprising a mRNA vaccine or protein subunit vaccine.
Smith et al. (‘089) disclose the preparation of SARS-CoV-2 vaccines comprising the S glycoprotein packaged in a nanoparticle formulation. Vaccine compositions may be administered as a single dose (primary immunization) or over multiple doses (booster immunization). The timing of the administration is also discussed (see col. 28; bridging paragraph, cols. 29-30). This teaching does not disclose the SARS-CoV-2 immunogen set forth in SEQ ID NO.: 329. Muik et al. (‘387) provides various coronavirus vaccine formulations comprising mRNAs encoding the SARS-CoV-2 S protein, or variants thereof, that correspond to SEQ ID NO.: 329 (see SEQ ID NO.: 74 and Appendix A). Gorman et al. (2021) clearly teaches that incorporating a boosting step into a SARS-CoV-2 immunization protocol is critical for developing a lasting immune response. The authors noted that the data suggests that while a single dose may prevent disease, two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.
Therefore, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to utilize the highly immunogenic SARS-CoV-2 spike immunogen of Muik et al. (‘387), in the immunization regimen of Smith et al. (‘089). It would also have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate one or more booster steps in the immunization regimen to maximize the immune response against SARS-CoV-2 as suggested by Gorman et al. (2021).
Correspondence
Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The Examiner can normally be reached Monday through Friday from 10:00 AM to 6:00 PM. A message may be left on the Examiner's voice mail service. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the Examiner are unsuccessful, the Examiner's supervisor, Michael Allen, Ph.D., can be reached at (571) 270-3497. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600.
Information regarding the status of an application may be obtained from the Patent Center. Status information for published applications may be obtained from the Patent Center. Status information for unpublished applications is available through the Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Respectfully,
/JEFFREY S PARKIN/Primary Examiner, Art Unit 1671
30 September, 2026
Appendix A
US-18-071-499-74
Sequence 74, US/18071499
Patent No. 12186387
GENERAL INFORMATION
APPLICANT: BioNTech SE (en)
TITLE OF INVENTION: CORONAVIRUS VACCINE (en)
FILE REFERENCE: 2013237-0518
CURRENT APPLICATION NUMBER: US/18/071,499
CURRENT FILING DATE: 2022-11-29
NUMBER OF SEQ ID NOS: 157
SEQ ID NO 74
LENGTH: 1268
TYPE: PRT
LOCATION: 1..1268
QUALIFIERS: mol_type = protein
organism = synthetic construct
Query Match 96.3%; Score 6469.5; Length 1268; Best Local Similarity 96.9%; Matches 1233; Conservative 10; Mismatches 22; Indels 7; Gaps 4;
Qy 1 MFVFLVLLPLVSSQCVMPLFNLITTTQSYTNSFTRGVYYPDKVFRSSVLHLTQDLFLPFF 60
|||||||||||||||| |||| ||||||||||||||||||||||||| |||||||||
Db 1 MFVFLVLLPLVSSQCV----NLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFF 56
Qy 61 SNVTWFHAISGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVN 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 57 SNVTWFHAISGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVN 116
Qy 121 NATNVFIKVCEFQFCNDPFLDV-YHKNNKSWMESESGVYSSANNCTFEYVSQPFLMDLEG 179
||||| |||||||||||||||| |||||||||||| |||||||||||||||||||||||
Db 117 NATNVVIKVCEFQFCNDPFLDVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEG 176
Qy 180 KQGNFKNLREFVFKNIDGYFKIYSKHTPI-IGRDFPQGFSALEPLVDLPIGINITRFQTL 238
||||||||||||||||||||||||||||| :||| |||||||||||||||||||||||||
Db 177 KQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLPQGFSALEPLVDLPIGINITRFQTL 236
Qy 239 LALNRSYLTPGDSSSGWTAGAADYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKC 298
|||:|||||||||||||||||| |||||||||||||||||||||||||||||||||||||
Db 237 LALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKC 296
Qy 299 TLKSFTVEKGIYQTSNFRVQPTESIVRFPNVTNLCPFHEVFNATRFASVYAWNRTRISNC 358
||||||||||||||||||||||||||||||:|||||| |||||||||||||||| |||||
Db 297 TLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNC 356
Qy 359 VADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIKGNEVSQIAPGQTGNIADY 418
|||||||||||||||||||||||||||||||||||||||||:||||||||||||||||||
Db 357 VADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADY 416
Qy 419 NYKLPDDFTGCVIAWNSNKLDSKHSGNYDYWYRSFRKSKLKPFERDISTEIYQAGNKPCK 478
||||||||||||||||||||||| |||:| || |||| ||||||||||||||||||||
Db 417 NYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCN 476
Qy 479 G-KGPNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF 537
| | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 477 GVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF 536
Qy 538 NFNGLTGTGVLTKSNKKFLPFQQFGRDIVDTTDAVRDPQTLEILDITPCSFGGVSVITPG 597
||||||||||||:||||||||||||||| |||||||||||||||||||||||||||||||
Db 537 NFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPG 596
Qy 598 TNTSNQVAVLYQGVNCTEVSVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYE 657
||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db 597 TNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYE 656
Qy 658 CDIPIGAGVCASYQTQTKSRQQAQSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTIS 717
||||||||:|||||||||| ::|:||||||||||||||||||||||||||||||||||||
Db 657 CDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTIS 716
Qy 718 VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEV 777
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 717 VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEV 776
Qy 778 FAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCL 837
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 777 FAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCL 836
Qy 838 GDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQ 897
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 837 GDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQ 896
Qy 898 MAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLFSTASALGKLQDVVNHNAQALNT 957
||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Db 897 MAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNT 956
Qy 958 LVKQLSSKFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRAS 1017
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 957 LVKQLSSKFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRAS 1016
Qy 1018 ANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAI 1077
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1017 ANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAI 1076
Qy 1078 CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPL 1137
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1077 CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPL 1136
Qy 1138 QLELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQ 1197
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1137 QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQ 1196
Qy 1198 ELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDS 1257
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1197 ELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDS 1256
Qy 1258 EPVLKGVKLHYT 1269
||||||||||||
Db 1257 EPVLKGVKLHYT 1268